Publication | Closed Access

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

Malignant Pleural MesotheliomaPlacebo-controlled Phase 3MedicinePleural DiseaseBest Investigator ChoiceOncologyRadiation OncologyCancer ResearchRadiologyHealth Sciences